93534-20-4

Basic information

• Product Name: 1-(2, 4-dichlorophenyl)-2-phenylethan-1-one
• Synonyms: 1-(2, 4-dichlorophenyl)-2-phenylethan-1-one
• CAS NO: 93534-20-4
• Molecular Weight: 265.139
• Mol File: 93534-20-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-(2, 4-dichlorophenyl)-2-phenylethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2, 4-dichlorophenyl)-2-phenylethan-1-one(93534-20-4)
• EPA Substance Registry System: 1-(2, 4-dichlorophenyl)-2-phenylethan-1-one(93534-20-4)

Safety Data

• Hazardous Substances Data: 93534-20-4(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 103-80-0 phenylacetyl chloride 
• 541-73-1 1,3-Dichlorobenzene 
• 2123-27-5 2,4-dichlorostyrene 
• 100-63-0 phenylhydrazine 

Downstream Products

• 74613-73-3 2-bromo-1-(2,4-dichlorophenyl)-2-phenylethanone 

Relevant articles and documents

Metal-free synthesis of ketones by visible-light induced aerobic oxidative radical addition of aryl hydrazines to alkenes

A green and cost-effective method has been developed for the conversion of alkenes to ketones under metal-free conditions. The reaction involves the oxidative addition of alkenes with aryl radicals, which are generated by visible-light induced aerobic oxidation of arylhydrazines. The key features of this reaction include broad substrate scope, readily available reagents and amenability to gram-scale synthesis.

Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition

Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 μM). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.

Kinetics of silver(I) catalysed peroxydisulphate oxidation of benzylphenylglycollic acids

Ag(I) catalysed peroxydisulphate oxidation of benzylphenylglycollic and substituted benzylphenylglycollic acids in acetic acid-water mixture (30percent v/v) at constant ionic strength is first order each in and and independent of .Addition of allyl acetate inhibits the reaction.The thermodynamic parameters have been evaluated.The log k1 values have been fitted with ?+ values and the value of ρ+ calculated.The rate laws have been proposed on the basis of free radical mechanism involving silver(I).